Piramal Pharma Limited

₹246.20As of Sun 8 Nov 2026, 12:00 UTC
NSE:PPLPHARMAHealthcare
Country India
PE (Fwd) •••
TSR 4Y CAGR 11.17%
Div yield —
ROE (2.58%)
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.22
PE TTM —
TSR TTM 23.33%
Mkt cap ₹327.3B
ROIC (22.17%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
₹271
10.13%
(90.33%)
Hold 2|12|11|10|5
3Q26
4Q26
1Q27
2Q27
Earnings per share₹
2.24
2.32
2.48
2.73
10.20%
18.56%
15.91%
30.30%
Revenue₹B
19.09
19.08
19.31
19.09
4.61%
4.54%
3.06%
(2.20%)
Peers (US$3.382B)
Cap (US$)
PE
4.390B
32.67x
3.379B
76.44x
Capital
TTM
5Y
10Y
Leveragex
0.493
(0.097)
(0.075)
EBIT/Intx
0.938
0.791
0.727
Own earn%
26.46
(0.89)
(6.37)
Sh yield%
30.03
19.20
17.21
Owners
Insiders/Inst%
0.41
46.60
Short interest%
3.54
SBC / revenue%
5.58
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
16
Op margin range%
8–15
$1 testx
—
Incr. ROIC%
4